OCC Trading, page-1746

I always assumed a hefty capital injection would be all but needed on the back of FDA approval in H1 2025 in order to ramp up production. Just how they intend go about the raise is the ambiguous part to me.

I agree though, shoddy work from Paul to dislcose his belief the company won't be CF+ until 2027. He certainly could have worded it better, or at the very least, avoided the question more in line to that of a politician.

Have you spoken to John about this particular gaff since it was made or was it just via email?

I'd call Paul again, but honestly, I can't see the point. Everything is laid out before us, it's just a matter of one's time horizon and/or opportunity cost if investors choose to stick around here until early next year and then possibly even sell into the FDA news.